What is the appropriate starting dose, titration schedule, monitoring parameters, and contraindications for spironolactone (Aldactone) in a patient?

Spironolactone (Aldactone) Dosing and Management

For heart failure with reduced ejection fraction (HFrEF), start spironolactone at 25 mg once daily in patients with adequate renal function (eGFR >50 mL/min/1.73 m²) and normal potassium (≤5.0 mEq/L), titrating to 50 mg daily after 4-8 weeks if tolerated. 1, 2, 3

Starting Dose by Clinical Indication

Heart Failure (HFrEF)

• Standard dosing (eGFR >50 mL/min/1.73 m²): Start 25 mg once daily 1, 2, 4
• Reduced renal function (eGFR 30-50 mL/min/1.73 m²): Start 12.5-25 mg once daily or 25 mg every other day 2, 4
• Target maintenance dose: 50 mg once daily 1, 2, 3

Hypertension

• Initial dose: 25-100 mg daily in single or divided doses 4
• Titration: Increase at 2-week intervals; doses >100 mg/day provide minimal additional benefit 4

Edema/Cirrhosis

• Initial dose: 100 mg daily (range 25-200 mg), administered in hospital setting with slow titration 4

Primary Hyperaldosteronism

• Dose range: 100-400 mg daily for surgical preparation or long-term maintenance 4

Absolute Contraindications

Do not initiate spironolactone if: 2, 3, 4

• Baseline serum potassium ≥5.0 mEq/L
• Serum creatinine >2.5 mg/dL in men or >2.0 mg/dL in women
• eGFR <30 mL/min/1.73 m²
• Addison's disease
• Concomitant eplerenone use

Titration Schedule

Initial Phase (Weeks 0-8)

• Week 0: Check baseline potassium and creatinine before starting 1, 2
• Days 3-7: Recheck potassium and creatinine 2, 4
• Week 1: Recheck potassium and creatinine 1, 5, 4
• Week 4: Recheck potassium and creatinine 1, 5

Dose Escalation (After 4-8 Weeks)

• If potassium <5.5 mEq/L and creatinine stable: Increase to 50 mg daily 1, 2, 3
• Recheck labs at 1 and 4 weeks after dose increase 1, 5

Maintenance Monitoring

• Months 1-6: Check potassium and creatinine at 1,2,3, and 6 months 1, 5
• After 6 months: Check every 6 months if stable 1, 5
• More frequent monitoring required with: concurrent ACE inhibitor/ARB dose changes, clinical instability, baseline renal impairment, elderly patients, or diabetes 2, 6

Management of Adverse Effects

Hyperkalemia Management

Potassium 5.5-5.9 mEq/L:

• Reduce dose by 50% (e.g., 25 mg daily → 25 mg every other day) 1, 5, 6
• Monitor potassium closely 1, 5

Potassium ≥6.0 mEq/L:

• Stop spironolactone immediately 1, 5, 6, 4
• Initiate hyperkalemia treatment 1, 6
• Monitor potassium closely 1, 5
• Consider restarting at reduced dose only after potassium <5.0 mEq/L for ≥72 hours 2, 6

Worsening Renal Function

Creatinine >220 µmol/L (2.5 mg/dL):

• Reduce dose by 50% 1, 5, 6
• Monitor closely 1, 5

Creatinine >310 µmol/L (3.5 mg/dL):

• Stop spironolactone immediately 1, 5, 6
• Evaluate for renal-specific therapy 1, 6

Gynecomastia

• Occurs in ~9% of male patients at mean dose 26 mg daily 5, 4
• Onset varies from 1-2 months to >1 year 4
• Management: Switch to eplerenone 5, 1, 5
• Usually reversible after discontinuation 4

Critical Drug Interactions and Precautions

Medications to Avoid or Adjust

• Discontinue or reduce potassium supplements before initiating spironolactone 2, 6
• Avoid NSAIDs and COX-2 inhibitors (increase hyperkalemia risk) 2, 6, 4
• High-dose ACE inhibitors (captopril ≥75 mg, enalapril/lisinopril ≥10 mg daily) increase hyperkalemia risk 2, 6
• Never combine ACE inhibitor + ARB + spironolactone (triple RAAS blockade) 2

Temporary Holds Required

• During acute diarrhea or dehydration (heightens hyperkalemia risk) 2, 6
• When loop diuretic interrupted due to worsening renal function 2, 6

High-Risk Populations Requiring Enhanced Monitoring

Elderly Patients (≥75 Years)

• Higher propensity for hyperkalemia and renal decline 5, 1, 6
• Median dose achieved ~20 mg/day in clinical practice 7
• Discontinuation rates reach 30% in first year 7
• More frequent potassium/creatinine monitoring essential 6

Patients with Diabetes

• Increased hyperkalemia susceptibility, especially with insulin 6
• Enhanced monitoring required 6

Baseline Renal Insufficiency

• Intensive laboratory surveillance mandatory 6
• Consider every-other-day dosing for eGFR 30-49 mL/min/1.73 m² 2, 4

Evidence-Based Indications for Heart Failure

Class I recommendation for patients with: 5, 1, 2, 3

• LVEF ≤35%
• NYHA class II-IV symptoms
• Optimal beta-blocker AND ACE inhibitor (or ARB, but not both)
• NYHA class II patients require prior cardiovascular hospitalization or elevated natriuretic peptides 2, 3

Post-MI indication: 5, 1, 2

• LVEF ≤40%
• Heart failure symptoms or diabetes
• Within 3-14 days of acute MI

Common Clinical Pitfalls to Avoid

Do Not Permanently Discontinue for Mild Hyperkalemia

• Potassium 5.0-5.5 mEq/L: Attempt dose reduction and address reversible causes before stopping 6
• Spironolactone retains mortality/morbidity benefits even with potassium >5.5 mEq/L in major trials 6

Do Not Down-Titrate RAAS Inhibitors Solely for Hyperkalemia

• Employ potassium binders or conservative measures to preserve proven outcome benefits of ACE inhibitors/ARBs 6

Evaluate Alternative Causes of Hyperkalemia

• Acute heart failure decompensation 6
• Progressive kidney disease 6
• Dietary potassium intake 2
• Other medications 2, 6

Low-Dose Strategy Preferred Over Discontinuation

• In patients unable to tolerate target doses (50 mg), continuing lower doses (12.5-25 mg) is superior to stopping treatment 7, 8
• Discontinuation associated with 2-4 fold higher risk of subsequent cardiovascular events 7
• Doses as low as 12.5-25 mg daily effectively block aldosterone while minimizing hyperkalemia risk 8

Additional Monitoring Parameters

Beyond potassium and creatinine, monitor: 4

• Sodium (risk of hyponatremia)
• Magnesium (risk of hypomagnesemia)
• Calcium (risk of hypocalcemia)
• Uric acid (asymptomatic hyperuricemia common)
• Blood glucose (risk of hyperglycemia)